Anterogen.Co.,Ltd. (KOSDAQ:065660)
37,100
+900 (2.49%)
At close: Dec 5, 2025
Anterogen.Co.,Ltd. Revenue
Anterogen.Co.,Ltd. had revenue of 2.04B KRW in the quarter ending September 30, 2025, with 7.39% growth. This brings the company's revenue in the last twelve months to 7.32B, up 5.30% year-over-year. In the year 2024, Anterogen.Co.,Ltd. had annual revenue of 6.93B with 6.66% growth.
Revenue (ttm)
7.32B
Revenue Growth
+5.30%
P/S Ratio
50.71
Revenue / Employee
n/a
Employees
n/a
Market Cap
371.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.93B | 432.62M | 6.66% |
| Dec 31, 2023 | 6.50B | -90.76M | -1.38% |
| Dec 31, 2022 | 6.59B | -1.53B | -18.85% |
| Dec 31, 2021 | 8.12B | 3.97B | 95.64% |
| Dec 31, 2020 | 4.15B | 3.67M | 0.09% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |